Coulter Partners continues partnership with iOnctura and places new Chief Financial Officer
London, July 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Steven Sciuto as Chief Financial Officer.
iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.
Steven Sciuto is a seasoned finance executive with more than 15 years of corporate finance leadership and capital markets experience within the life sciences industry. He has played pivotal roles in scaling financial operations, raising over $400 million through private and public financing, and leading complex transactions. Prior to joining iOnctura, Steven was most recently at Neurogene Inc., where he held various roles of increasing responsibility within the finance organization, culminating as Vice President of Finance.
“I am excited to join iOnctura at such a pivotal time in its growth,” said Steven Sciuto, CFO of iOnctura. “With a strong foundation already in place, and an unrelenting mission to combat rare and hard-to-treat cancers, I look forward to working with the talented team at iOnctura to drive financial and strategic initiatives, to accelerate development and ensure sustainable success over the coming years.”
Catherine Pickering, CEO and co-founder of iOnctura said, “Following our successful initiation of a number of Phase II studies for our lead asset, roginolisib, we are committed to building a world-class Leadership Team that not only delivers on the promise of this asset but also strengthens our entire portfolio. As we enter the next phase of our strategy, every new leader has been carefully chosen for their expertise, vision and ability to drive transformative growth – and Steve joins us to do just that. Together, we will propel the Company forward, ensuring we are well-positioned for the next chapter of our journey and sustained success.”
Dr. Pickering added, “We were impressed with Coulter Partners‘ seamless execution of this search. Their extensive network in the CFO market ensured a consistent stream of high-caliber candidates, providing us with a diverse pool to choose from. Coulter Partners’ ability to leverage their insights and provide valuable market intelligence on candidate profiles truly supported our decision-making process and ultimately led us to an exceptional fit for iOnctura.”
[ENDS]
Notes to editors:
About iOnctura
iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Lead asset, roginolisib, is an allosteric modulator of PI3Kδ with a unique chemical structure and binding mode. Allosteric modulation is a new archetype for precise inhibition of PI3Kδ, promising clinical activity without the detrimental tolerability seen with previous generations of inhibitors. Roginolisib is being investigated in multiple randomized Phase II studies in solid and hematological malignancies. iOnctura BV is headquartered in Amsterdam, The Netherlands with its wholly owned Swiss subsidiary, iOnctura SA, located in Geneva, Switzerland. iOnctura is backed by specialist institutional investors including Syncona, M Ventures, Inkef Capital, EIC Fund, VI Partners, Schroders Capital and XGEN Venture.
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
